1. Market Research
  2. > Aneurysmal Subarachnoid Hemorrhage (SAH) – Pipeline Review, H1 2013

Aneurysmal Subarachnoid Hemorrhage (SAH) – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH). Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Aneurysmal Subarachnoid Hemorrhage (SAH).
- A review of the Aneurysmal Subarachnoid Hemorrhage (SAH) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Aneurysmal Subarachnoid Hemorrhage (SAH).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Aneurysmal Subarachnoid Hemorrhage (SAH) Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Aneurysmal Subarachnoid Hemorrhage (SAH) 6
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics under Development by Companies 8
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Products under Development by Companies 11
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Products under Investigation by Universities/Institutes 12
Companies Involved in Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics Development 13
Aneurysmal Subarachnoid Hemorrhage (SAH) - Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Molecule Type 14
Drug Profiles 16
nimodipine - Drug Profile 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
tiopronin - Drug Profile 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Drug Profile Updates 18
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Discontinued Products 19
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Dormant Products 20
Aneurysmal Subarachnoid Hemorrhage (SAH) - Product Development Milestones 21
Featured News and Press Releases 21
Oct 04, 2010: Edge Provides Update On NimoGel 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23



List of Tables

Number of Products Under Development for Aneurysmal Subarachnoid Hemorrhage (SAH), H1 2013 6
Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH) - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Number of Products under Investigation by Universities/Institutes, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 12
Assessment by Monotherapy Products, H1 2013 13
Assessment by Stage and Molecule Type, H1 2013 15
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Drug Profile Updates 18
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Discontinued Products 19
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Dormant Products 20



List of Figures

Number of Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH), H1 2013 6
Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH) - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Products under Investigation by Universities/Institutes, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Assessment by Monotherapy Products, H1 2013 13
Assessment by Molecule Type, H1 2013 14
Assessment by Stage and Molecule Type, H1 2013 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.